BRISBANE, Calif., April 10 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of the clinical program for the company's lead product candidate, BSI-201, into glioblastoma multiforme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback